Evommune, Inc. 8-K

What Happened

• On June 29, 2026, Evommune, Inc. filed an 8-K and issued a press release announcing top-line results from its randomized, double‑blind, placebo‑controlled, dose‑ranging Phase 2b trial of oral MRGPRX2 antagonist EVO756 in adults with moderate-to-severe chronic spontaneous urticaria (CSU).
• The trial enrolled 160 moderate-to-severe, antihistamine‑refractory CSU patients across the United States, Europe, Canada and Japan. The study did not meet its primary endpoint — mean change in Urticaria Activity Score over seven days (UAS7) at 12 weeks — at any dose.
• Based on these results, Evommune plans to cease development of EVO756 for CSU, while stating it will continue to evaluate EVO756 in other indications.

Key Details

• Filing date and announcement: June 29, 2026 (press release furnished as Exhibit 99.1 in the 8-K).
• Trial size and scope: 160 patients; randomized, double‑blind, placebo‑controlled, dose‑ranging; sites in U.S., Europe, Canada and Japan.
• Primary endpoint: Mean change in UAS7 at 12 weeks — not met at any dose.
• Corporate action: Company will stop developing EVO756 for CSU but may pursue other indications.

Why It Matters

• For investors, failure to meet the Phase 2b primary endpoint and the decision to stop CSU development removes a near-term clinical opportunity from Evommune’s pipeline, which could affect valuation tied to EVO756’s CSU potential.
• The company retains optionality by exploring EVO756 in other indications, but those prospects are uncertain and subject to additional clinical data and regulatory paths. The 8-K also includes standard forward‑looking statements and risk‑factor references.